Aimmune Therapeutics Stock Nabs Record High After Drug Data

A short squeeze could push AIMT even higher

Managing Editor
Feb 20, 2018 at 10:25 AM
facebook X logo linkedin


Aimmune Therapeutics Inc (NASDAQ:AIMT) stock is in focus this morning, after the company's peanut allergy drug AR101 met its late-stage study goals. Aimmune will now seek U.S. approval by the end of 2018. After being halted in pre-market trading, AIMT stock is up 1.3% to trade at $37.30, and touched a fresh record high of $42 out of the gate this morning.

The stock has been climbing since October, when rival DBV Technologies reported its treatment failed in a late-stage study. AIMT recently found strong support from the 80-day moving average, and overall has added nearly 87% year-over-year.

Short sellers have been in covering mode for a while now. Short interest has almost been cut in half since early September, but still represents more than 9% of the stock's total available float, and nearly six days of pent-up buying demand, at AIMT's average daily trading volume. This signals ample sideline cash available to help fuel the equity's fire. 

However, anyone looking to use options to speculate on Aimmune Therapeutics with options better be willing to pay up. The equity's Schaeffer's Volatility Index (SVI) of 178% ranks in the 96th percentile of its annual range. Said differently, volatility expectations are extremely high for near-term options at the moment.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI